Try our mobile app
US Leaders — Screener 

Technology
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Apple 351.98 -1.2% 0.3% 2.4% 
11.7% 
9.9%
10.8% 
9.4%
30.3x
Microsoft 517.95 -1.1% 0.7% 0.5% 
18.8% 
24.6%
21.7% 
20.4%
18.8x
Google 281.81 -3.7% 0.3% 2.3% 
24.7% 
32.9%
28.8% 
21.4%
18.7x
Amazon 257.85 -3.3% 0.0% -2.0% 
12.1% 
43.3%
27.7% 
24.9%
16.6x
Broadcom 332.99 -4.0% 0.7% 2.3% 
85.5% 
173.9%
129.7% 
41.8%
38.9x
Facebook 626.13 -2.4% 0.3% -1.2% 
26.1% 
-21.0%
2.5% 
29.7%
16.0x
Texas Instruments 294.26 -3.1% 1.9% 3.3% 
27.7% 
58.3%
43.0% 
6.8%
26.5x
Netflix 60.74 -2.3% 0.0% 3.8% 
11.9% 
36.9%
24.4% 
28.8%
16.4x
Salesforce 215.23 -1.2% 0.8% 7.2% 
10.8% 
5.2%
8.0% 
19.4%
16.8x
Adobe 246.82 +1.5% 0.0% 9.4% 
12.9% 
7.9%
10.4% 
13.2%
9.5x

Payments
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Visa 426.08 +0.1% 0.6% 2.6% 
13.2% 
17.9%
15.6% 
11.6%
33.0x
Mastercard 661.61 +0.1% 0.5% 2.3% 
14.0% 
17.9%
15.9% 
12.5%
34.8x

Hardware
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Nvidia 155.69 -4.4% 0.3% 0.0% 
105.9% 
122.8%
114.3% 
116.3%
19.6x
QUALCOMM 169.60 -1.7% 2.1% 4.8% 
-8.4% 
-45.8%
-27.1% 
6.1%
18.7x

Communications
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Cisco 94.18 -1.5% 1.7% 2.7% 
24.4% 
54.9%
39.6% 
6.6%
19.5x
Verizon 46.29 -0.2% 6.1% 1.8% 
1.5% 
8.0%
4.7% 
1.4%
7.8x
AT&T 22.31 +0.6% 5.0% 9.1% 
5.3% 
-20.7%
-7.7% 
10.7%
7.3x
Comcast 25.50 +1.4% 5.2% 21.7% 
-6.1% 
-5.6%
-5.8% 
-1.4%
5.0x

Entertainment
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Disney 118.53 -0.4% 1.3% 2.1% 
6.8% 
14.5%
10.6% 
18.1%
10.5x

Consumer Brand
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Coca-Cola 99.25 0.0% 2.1% 4.1% 
7.4% 
11.0%
9.2% 
10.0%
26.3x
Procter & Gamble 172.72 +1.7% 2.5% 4.2% 
4.0% 
2.0%
3.0% 
0.3%
18.1x
Philip Morris 195.40 -1.8% 2.3% 4.6% 
5.5% 
12.8%
9.1% 
9.6%
18.9x
PepsiCo 146.30 +0.6% 4.0% 3.9% 
5.6% 
13.8%
9.7% 
8.0%
12.8x
Nike 38.05 +0.2% 4.3% 4.3% 
-4.3% 
-1.2%
-2.8% 
-0.2%
14.7x

Food
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
McDonalds 275.35 +1.2% 2.7% 4.0% 
1.1% 
6.8%
3.9% 
2.7%
18.2x

Retail
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Walmart 128.10 0.0% 0.8% 1.1% 
5.9% 
23.5%
14.7% 
9.8%
22.7x
Costco Wholesale 1 109.84 +0.3% 0.5% 2.0% 
11.1% 
20.0%
15.5% 
15.0%
31.8x
Home Depot 346.38 -0.7% 2.7% 3.4% 
5.7% 
8.1%
6.9% 
0.6%
16.4x

Pharma
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Eli Lilly 1 435.37 -0.6% 0.5% 0.0% 
38.6% 
57.1%
47.9% 
52.4%
31.2x
Johnson & Johnson 282.87 -1.0% 1.8% 8.4% 
5.9% 
-60.3%
-27.2% 
15.5%
25.8x
AbbVie 294.39 -0.2% 2.3% 2.9% 
10.3% 
39.8%
25.0% 
7.7%
24.1x
United Health 409.92 +0.6% 2.2% 5.4% 
-0.4% 
41.0%
20.3% 
1.9%
14.8x
Merck 145.64 -1.4% 2.3% 2.7% 
4.7% 
-7.1%
-1.2% 
15.8%
15.8x
Thermo Fisher Scientific 691.97 -1.2% 0.3% 4.0% 
9.1% 
18.6%
13.9% 
7.6%
25.5x
Abbott 107.80 -0.7% 2.3% -8.6% 
14.5% 
-27.0%
-6.3% 
5.8%
26.2x
Pfizer 28.92 +0.1% 6.0% 5.0% 
-0.4% 
-15.3%
-7.8% 
21.2%
10.6x
Danaher 230.99 -0.9% 0.7% -2.1% 
8.3% 
4.2%
6.3% 
-3.5%
30.4x
Bristol-Myers Squibb 62.99 -0.7% 4.0% 7.3% 
6.9% 
6.8%
6.9% 
16.7%
11.1x

Equipment
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Tesla 377.18 -3.3% 0.0% 0.1% 
-0.2% 
-23.4%
-11.8% 
-3.5%
152.5x
Raytheon Technologies 194.52 -2.0% 1.4% 3.3% 
11.1% 
21.9%
16.5% 
23.2%
19.0x

iconductors
Company / category Price and
change
Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA
AVG growth
last/hist
EV/LTM EBITDA Express
potential
Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Micron Technology 719.89 -7.5% 0.1% 4.5% 
200.0% 
200.0%
200.0% 
104.8%
7.8x
Market Attractiveness Index

Market Attractiveness Index

calculated as average express-upside for TOP-5 US companies with highest potential

High values of index (>30%), indicate favorable moments for additional cash contributions to the stock market / stock purchases

Current value of the Index is 99.4%

chart technology by TradingView

Invest in a rotating portfolio of top US-based, non-financial companies. Strategy results are shown below. This page contains financial information on the 40 companies we screen for our portfolio. For a detailed overview of our US Leaders strategy and rationale behind it, follow the link

US Leaders
since 2019-08-25

-3.1%

-2.1%
day

+2.6%

-2.1%
week

+304.1%

160.1%
Since inception

0.0%

SP500
Since inception
Actual Performance
Period Strategy SP&500
 
2019 +9.9% +13.5%
2020 +14.2% +16.2%
2021 +30.6% +27.4%
2022 -17.1% -19.7%
2023 +58.3% +24.2%
2024 +37.6% +23.5%
2025 +29.6% +16.4%
2026 +8.5% +8.1%
 
Annualized +21.4% +14.1%
 
Day -3.1% -2.1%
Week +2.6% -2.1%
Year to date +5.2% 0.0%
Since inception (2019-08-25) +304.1% +160.1%

Portfolio (USD) and S&P500 dynamics (%)
chart technology by TradingView

Reviews


2026-11-15
(review)
Weekly results
for USD strategies

US Leaders: +5.8%

Global Commodities: +2.4%

Trending Ideas: -2.5%

Rising Stars: -11.6%

vs S&P500: +2.5%


2026-11-13
#reports #CSCO

Cisco (Internet protocol (IP)-based networking manufacturer) reported for 2026 q3
(2026-05-13, After Market Close):

- Revenue +24.4% YoY (vs +17.6% in previous quarter and historical rate +5.4%)
- EBITDA +54.9% YoY (vs +31.0% in previous quarter and historical rate +7.8%)
- EBITDA margin 33.2% increased compared to 26.7% same period last year
- Net Debt increased by $0.3 bln since the start of the year (0.1% of market cap)
- FCF (LTM) +$10.4 bln (positive), 2.6% of market cap
- EV/EBITDA multiple is 20.7x compared to historical level (75th percentile) of 21.7x
expected multiple is 21x


Growth potential increased by 8.0% to +11.0%

2026-11-10
#reports #BRKB

Berkshire Hathaway (Insurance — Diversified) reported for 2026 q2
(2026-05-02, Before Market Open):

- Revenue +16.6% YoY (vs +14.2% in previous quarter and historical rate -4.3%)
- EBITDA -28.2% YoY (vs +107.5% in previous quarter and historical rate +6.5%)
- EBITDA margin 29.8% decreased compared to 48.3% same period last year
- EV/EBITDA multiple is 16.7x compared to historical level (75th percentile) of 12.1x


2026-11-10
#reports #BRKB

Berkshire Hathaway (Insurance — Diversified) reported for 2026 q3
(2026-05-02, Before Market Open):

- Revenue +16.6% YoY (vs +14.2% in previous quarter and historical rate -4.3%)
- EBITDA -28.2% YoY (vs +107.5% in previous quarter and historical rate +6.5%)
- EBITDA margin 29.8% decreased compared to 48.3% same period last year
- EV/EBITDA multiple is 16.7x compared to historical level (75th percentile) of 12.1x


2026-11-08
(review)
Weekly results
for USD strategies

US Leaders: -7.1%

Global Commodities: -6.5%

Trending Ideas: +1.0%

Rising Stars: +12.5%

vs S&P500: -2.7%


2026-11-06
#reports #MCD

McDonalds (Fast food chain) reported for 2026 q3
(2026-05-07, Before Market Open):

- Revenue +1.1% YoY (vs +3.7% in previous quarter and historical rate +3.7%)
- EBITDA +6.8% YoY (vs +3.3% in previous quarter and historical rate +1.7%)
- EBITDA margin 51.9% increased compared to 49.1% same period last year
- Net Debt decreased by $0.4 bln since the start of the year (0.2% of market cap)
- FCF (LTM) +$3.3 bln (positive), 1.7% of market cap
- EV/EBITDA multiple is 18.4x compared to historical level (75th percentile) of 22.5x
expected multiple is 18.5x


Growth potential increased by 2.3% to +29.2%

2026-11-05
#reports #V

Visa (Payment system) reported for 2026 q3
(2026-04-28, After Market Close):

- Revenue +13.2% YoY (vs +14.4% in previous quarter and historical rate +12.0%)
- EBITDA +17.9% YoY (vs +6.8% in previous quarter and historical rate +11.2%)
- EBITDA margin 49.4% increased compared to 47.5% same period last year
- Net Debt decreased by $1.8 bln since the start of the year (0.2% of market cap)
- FCF (LTM) +$16.9 bln (positive), 2.2% of market cap
- EV/EBITDA multiple is 32.5x compared to historical level (75th percentile) of 32.3x
expected multiple is 32.9x


Growth potential increased by 5.7% to -5.9%

2026-11-05
#reports #QCOM

QUALCOMM (Producer of semiconductor and telecommunications equipment ) reported for 2026 q3
(2026-02-04, After Market Close):

- Revenue -8.4% YoY (vs -4.0% in previous quarter and historical rate +6.7%)
- EBITDA -45.8% YoY (vs -36.0% in previous quarter and historical rate +5.5%)
- EBITDA margin 17.3% decreased compared to 29.2% same period last year
- Net Debt increased by $0.5 bln since the start of the year (0.3% of market cap)
- FCF (LTM) +$10.2 bln (positive), 5.5% of market cap
- EV/EBITDA multiple is 18.7x compared to historical level (75th percentile) of 18x
expected multiple is 18.2x

At the opening of the session the share price went down -10.7%

2026-11-05
#reports #PFE

Pfizer (The largest farm company) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=203169)
(2026-05-05, Before Market Open):

- Revenue -0.4% YoY (vs +2.6% in previous quarter and historical rate +12.0%)
- EBITDA -15.3% YoY (vs +11.5% in previous quarter and historical rate +30.4%)
- EBITDA margin 34.0% decreased compared to 39.9% same period last year
- Net Debt decreased by $3.2 bln since the start of the year (1.8% of market cap)
- FCF (LTM) +$0.1 bln (positive), 0.1% of market cap
- EV/EBITDA multiple is 11.1x compared to historical level (75th percentile) of 14.9x
expected multiple is 10.4x


2026-11-05
#reports #CVS

CVS health (Prescription drug provider) reported for 2026 q3
(2026-05-06, Before Market Open):

- Revenue +5.4% YoY (vs +7.3% in previous quarter and historical rate +22.9%)
- EBITDA +217100% YoY (vs +193.3% in previous quarter and historical rate +23.0%)
- EBITDA margin 2.0% increased compared to -3.9% same period last year
- Net Debt decreased by $1.5 bln since the start of the year (1.4% of market cap)
- FCF (LTM) +$15.6 bln (positive), 14.8% of market cap
- EV/EBITDA multiple is 13.7x compared to historical level (75th percentile) of 58.4x


2026-11-05
#reports #ABT

Abbott (Medical products and equipment manufacturer ) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=8&id=163146)
(2026-07-16, Before Market Open):

- Revenue +14.5% YoY (vs +13.0% in previous quarter and historical rate +6.5%)
- EBITDA -27% YoY (vs -13.0% in previous quarter and historical rate +5.1%)
- EBITDA margin 13.6% decreased compared to 21.4% same period last year
- Net Debt decreased by $0.2 bln since the start of the year (0.1% of market cap)
- FCF (LTM) -$16.1 bln (negative), 8.0% of market cap
- EV/EBITDA multiple is 27.7x compared to historical level (75th percentile) of 27.4x
expected multiple is 27.9x


2026-11-04
#reports #MRK

Merck (Medical products and equipment manufacturer) reported for 2026 q3
(2026-04-30, Before Market Open):

- Revenue +4.7% YoY (vs +5.1% in previous quarter and historical rate +4.4%)
- EBITDA -100% YoY (vs +0.9% in previous quarter and historical rate +19.5%)
- EBITDA margin 0.0% decreased compared to 45.7% same period last year
- Net Debt decreased by $2.5 bln since the start of the year (0.7% of market cap)
- FCF (LTM) +$4.4 bln (positive), 1.2% of market cap
- EV/EBITDA multiple is 22.3x compared to historical level (75th percentile) of 16.3x
expected multiple is 15.6x


2026-11-04
#reports #BMY

Bristol-Myers Squibb ( Pharmaceutical and nutritional products manufacturer ) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=202757)
(2026-04-30, Before Market Open):

- Revenue +6.9% YoY (vs +5.7% in previous quarter and historical rate +3.7%)
- EBITDA +6.8% YoY (vs +14.1% in previous quarter and historical rate +29.7%)
- EBITDA margin 31.3% has not changed compared to 31.4% same period last year
- Net Debt decreased by $1.1 bln since the start of the year (0.9% of market cap)
- FCF (LTM) +$7.6 bln (positive), 6.1% of market cap
- EV/EBITDA multiple is 11.3x compared to historical level (75th percentile) of 19.6x
expected multiple is 10.7x


2026-11-04
#reports #DD

DuPont (Chemical materials producer ) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=203123)
(2026-05-05, Before Market Open):

- Revenue -39.2% YoY (vs -44.2% in previous quarter and historical rate -13.8%)
- EBITDA -2.7% YoY (vs -11.0% in previous quarter and historical rate +0.7%)
- EBITDA margin 34.3% increased compared to 21.5% same period last year
- Net Debt increased by $0.1 bln since the start of the year (0.1% of market cap)
- FCF (LTM) +$0 bln (positive), 0.0% of market cap
- EV/EBITDA multiple is 48x compared to historical level (75th percentile) of 28.2x


2026-11-04
#reports #AMGN

Amgen (Medicines manufacturer for grievous illnesses) reported for 2026 q3
(2026-04-30, After Market Close):

- Revenue +8.5% YoY (vs +9.5% in previous quarter and historical rate +14.6%)
- EBITDA +81.9% YoY (vs +29.9% in previous quarter and historical rate +29.0%)
- EBITDA margin 48.4% increased compared to 28.9% same period last year
- Net Debt decreased by $2.5 bln since the start of the year (1.0% of market cap)
- FCF (LTM) +$5.9 bln (positive), 2.4% of market cap
- EV/EBITDA multiple is 10.9x compared to historical level (75th percentile) of 17.2x


2026-11-04
#reports #AMD

Advanced Micro Devices (Semiconductor manufacturer) reported for 2026 q3
(2026-05-05, After Market Close):

- Revenue +79.8% YoY (vs +34.1% in previous quarter and historical rate +22.2%)
- EBITDA +132.9% YoY (vs +53.9% in previous quarter and historical rate +85.2%)
- EBITDA margin 26.9% increased compared to 20.8% same period last year
- Net Debt decreased by $0.2 bln since the start of the year (0.0% of market cap)
- FCF (LTM) +$11.8 bln (positive), 1.5% of market cap
- EV/EBITDA multiple is 89.1x compared to historical level (75th percentile) of 98.9x


2026-11-03
#reports #UNH

United health (Biotechnology) reported for 2026 q3
(2026-07-16, Before Market Open):

- Revenue -0.4% YoY (vs +0.4% in previous quarter and historical rate +7.8%)
- EBITDA +41% YoY (vs +44.9% in previous quarter and historical rate -4.1%)
- EBITDA margin 6.8% increased compared to 4.8% same period last year
- Net Debt increased by $3.7 bln since the start of the year (1.0% of market cap)
- FCF (LTM) +$15 bln (positive), 4.1% of market cap
- EV/EBITDA multiple is 14.6x compared to historical level (75th percentile) of 16.2x
expected multiple is 13.7x


Growth potential decreased by 6.6% to +13.5%

2026-11-03
#reports #ABBV

AbbVie ( Medicines manufacturer) reported for 2026 q3
(2026-02-04, Before Market Open):

- Revenue +10.3% YoY (vs +10.2% in previous quarter and historical rate +6.3%)
- EBITDA +70.8% YoY (vs +17.2% in previous quarter and historical rate +11.6%)
- EBITDA margin 46.9% increased compared to 30.3% same period last year
- Net Debt increased by $5.5 bln since the start of the year (1.1% of market cap)
- FCF (LTM) +$17.8 bln (positive), 3.5% of market cap
- EV/EBITDA multiple is 21.8x compared to historical level (75th percentile) of 23.2x
expected multiple is 23.5x

At the opening of the session the share price went down -7.0%

Growth potential increased by 17.4% to +14.5%

2026-11-03
#reports #AAPL

Apple ( Personal and tablet computers, smartphones, software manufacturer) reported for 2026 q3
(2026-04-30, After Market Close):

- Revenue +11.7% YoY (vs +16.4% in previous quarter and historical rate +8.0%)
- EBITDA +9.9% YoY (vs +25.7% in previous quarter and historical rate +10.8%)
- EBITDA margin 34.1% decreased compared to 34.7% same period last year
- Net Debt increased by $19.9 bln since the start of the year (0.4% of market cap)
- FCF (LTM) +$95.9 bln (positive), 2.0% of market cap
- EV/EBITDA multiple is 28.5x compared to historical level (75th percentile) of 29.5x
expected multiple is 26.7x


Growth potential decreased by 3.0% to +5.1%

2026-11-01
(review)
Weekly results
for USD strategies

US Leaders: -0.1%

Global Commodities: +0.4%

Trending Ideas: 0.0%

Rising Stars: +3.4%

vs S&P500: -0.6%


2026-10-30
#reports #TMO

Thermo Fisher Scientific (Medical equipment manufacturer) reported for 2026 q3
(2026-07-23, Before Market Open):

- Revenue +9.1% YoY (vs +10.5% in previous quarter and historical rate +3.0%)
- EBITDA +18.6% YoY (vs +15.2% in previous quarter and historical rate +12.3%)
- EBITDA margin 25.4% increased compared to 23.4% same period last year
- Net Debt decreased by $2.6 bln since the start of the year (1.0% of market cap)
- FCF (LTM) +$8.6 bln (positive), 3.3% of market cap
- EV/EBITDA multiple is 25.4x compared to historical level (75th percentile) of 25x
expected multiple is 25.2x


Growth potential increased by 3.4% to +0.3%